CABA

$2.71-$0.14 (-4.91%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$464.7M

163M shares

52-week range

$1.40 – $4.23

46% from low

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Exchange

NASDAQ

Change$-4.66

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$3M	-42.9%	$-1.37	$-1.62–$-0.99	—	5
2027	$712586	-71.5%	$-1.24	$-1.65–$-0.89	—	5
2028	$72M	+9955.0%	$-1.11	$-2.35–$-0.46	—	7
2029	$380M	+430.0%	$-0.65	$-0.65–$-0.65	—	2

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 5 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-13	$-0.37	$-0.34	+8.8%
2026-05-14	$-0.41	$-0.39	+4.9%
2026-03-23	$-0.45	$-0.40	+11.1%
2025-11-10	$-0.49	$-0.44	+10.2%
2025-08-07	$-0.71	$-0.73	-2.8%
2025-05-15	$-0.67	$-0.71	-6.0%
2025-03-31	$-0.65	$-0.65	+0.0%
2024-11-14	$-0.59

DCF fair valuemodel estimate

Intrinsic value

$0.49

Price

$2.71

Implied downside

-82%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
CABACabaletta Bio, Inc.	$2.71	-4.91%	$442M	—
ALLOAllogene Therapeutics, Inc.	$1.98	-4.35%	$683M	—
AVIRAtea Pharmaceuticals, Inc.	$5.07	+0.20%	$406M	—
CAPRCapricor Therapeutics, Inc.	$4.21	+0.48%	$242M	—
EDITEditas Medicine, Inc.	$2.81	-1.06%

Cabaletta Bio, Inc. Common Stock

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

www.cabalettabio.com

Employees: 158
IPO / List date: Oct 25, 2019
HQ: PHILADELPHIA, PA

Held by traders on TradeandTell

No one on the platform currently holds CABA.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	2,036,663	$5.5M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded CABA yet.

$CABA chatter on StockTwits

Tom Wilburn@Bungfolio5h
@Aaodania Will look at $CABA after this $SLS Phase3 results or BuyOut nuke blows the shorts to smitherines (and my bank account). All extra fundage earmarked for $SLS
View on StockTwits ↗
10xorbust@10xorbust5h
@Aaodania $CABA is an amazing biotech for sure with many of the biggest biotech specialist, investors, owning big portions of companies (Bain Capital life Sciences owns at least 9.9% of the company) and Eli Lilly owning part of the company with his head of research on scientific board of advisor. CABA is currently in phase 2 trials. But, the big catalysts are further off than $SLS so right now it is very cheap. It is a great time to accumulate. But if you need the big money, take advantage of SLS catalysts right NOW that’s a different issue.
View on StockTwits ↗
A A@AaodaniaBullish6h
$SLS $CABA . Please see $CABA. It is amazing.
View on StockTwits ↗
Aura@ExploringTradesBullish10h
Put ticker JUNS onto your watchlist right now! JUNS has only 770k shares outstanding and only 480k shares public float. Look at what SDOT / YXT / DFNS / AKAN did on similar share numbers recently! JUNS has a similar move coming - Added a big position for a squeeze. $CABA $AFRM in
View on StockTwits ↗
Moonman321@Moonman321Bullish11h
$CABA $IWM $PLUG $QQQ $SIDU PPI came back good today 📉🔥 Small Caps didn’t explode immediately — and that’s fine. This feels like the delay before takeoff. Shake out the weak hands, let the market digest the numbers, then watch what happens tomorrow heading into the weekend. 🚀 Small Caps are just getting started.
View on StockTwits ↗
ABDULMOHSEN@ABDULMOHSEN0811h
$CABA It's truly shameful and deceptive that some are spreading news about the stock, claiming it's promising. They might be telling the truth, but now is not the right time to invest. There's still a long way to go to complete the trials and obtain the necessary approvals. All of this will happen in late 2027 or early 2028 if the company's trials are successful. But I think it's premature to talk about making profits now, even if you wait until 2026 or early 2027. That won't happen now. Now is not the time to invest in this stock.
View on StockTwits ↗
Joe E Costa@Jarvis7424Bullish11h
$CABA seemed like good earnings to me??
View on StockTwits ↗
Venice@venice868Bearish14h
$CABA Each common stock warrant has an exercise price per share of $2.50. The common stock warrants are immediately exercisable from the date of issuance and will expire on September 12, 2026, fifteen months from the date of issuance. Aggregate net proceeds were $93,558 after deducting underwriting discounts and commissions and offering expenses. As of June 30, 2026, 4,800,000 pre-funded warrants had been exercised and 6,000,000 remain outstanding. In addition, as of June 30, 2026, 5,275,100 common stock warrants had been exercised for proceeds of $13,188 and 47,815,090 common stock warrants remain outstanding. Read 10-Q
View on StockTwits ↗
Viktorio07@Viktor4o14h
$CABA Whats wrong with that stock??? Institutions are accumulated and the price is going down!? Doesn't make any sense isn't it?
View on StockTwits ↗
Moonman321@Moonman321Bullish14h
$CABA 🐻 🩸 $CABA 😂 Ahhh, now I see what confused you. You read “going concern” and stopped there. Try reading the rest of the filing. CABA raised roughly $141M net, has a substantially stronger cash position, and says it expects that funding to carry operations into mid-2027. Meanwhile, the actual biotech story is advancing registrational programs, strong autoimmune CAR-T data and commercial-scale manufacturing. But sure, stare at one scary accounting phrase and wonder why the stock didn’t react the way you expected. 🤦‍♂️
View on StockTwits ↗
Moonman321@Moonman321Bullish15h
$CABA last shakeout
View on StockTwits ↗
ABDULMOHSEN@ABDULMOHSEN0815h
$CABA I don't see any impact of the financial results report on the stock price 🙄
View on StockTwits ↗
Paul M@THE_MADMAN16h
$CABA glad I got out... They got little cash and a big diluted raise is coming. No wonder why the results never moved the needle. Heaps of bios are ripping but this dog is doing nothing. Reason for that behind the curtains
View on StockTwits ↗
SignoreRossi@SignoreRossiBullish16h
$CABA Business as usual here I would say. No big surprises - steps up will only happen with good new data in October / November. Not much will happen till then - for some it may look boring, for me it’s a very exciting stock and technology which will bring very good money by time.
View on StockTwits ↗
Stocktwits Earnings@StocktwitsEarnings17h
$CABA Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.34 up 53.42% YoY
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.